Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATURNE trial of sunitinib plus TACE versus placebo plus TACE in unresectable hepatocellular carcinoma
2009-017064-16Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Dec 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sunitinib and doxorubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Severe bleeding or severe hepatic failure within 1 week after chemoembolization sessions. Started Dec 2009; status: completed.
02
Drugs
sunitinibdoxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2009-017064-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017064-16.